ABATACEPT: A NEW CHOICE FOR CHILDREN WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
Abstract
Key words: children, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, abatacept, inactive disease status, T-cell co-stimulation.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(2):32-39)
References
1. Oliveira S., Ravelli A., Pistorio A. et al. Proxy-reported healthrelated quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization
2. multinational quality of life cohort study. Arthritis Rheum. 2007; 57 (1): 35–43.
3. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369 (9563): 767–778.
4. Ruperto N., Levinson J., Ravelli A. et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome
5. status. J. Rheumatol. 1997; 24 (5): 945–951.
6. Giannini E., Brewer E., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A. – U.S.S.R. double blind, placebo controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N. Engl. J. Med. 1992; 326 (16): 1043–1049.
7. Ravelli A., Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J. Rheumatol. 2000; 27 (8): 1830–1833.
8. Ruperto N., Murray K.J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50 (7): 2191–2201.
9. Lovell D., Giannini E., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000; 342 (11): 763–769.
10. Ruperto N., Lovell D., Cuttica R. et al. A randomized, placebocontrolled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. 2007. In press.
11. Ruperto N., Lovell D., Goodman S. et al. 48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA). Ann Rheum. Dis. 2006; 65 (Suppl. 11): 56.
12. Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum. Dis. 2004; 63 (12): 1638–1644.
13. Quartier P., Taupin P., Bourdeaut F. et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003; 48 (4): 1093–1101.
14. Yamada A., Salama A., Sayegh M. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 2002; 13 (2): 559–575.
15. Kremer J., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003; 349 (20): 1907–1915.
16. Kremer J., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a Phase IIb, double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2005; 52 (8): 2263–2271.
17. Kremer J., Genant H., Moreland L. et al. Effects of abatacept in patients with active rheumatoid arthritis despite methotrexate: a randomized trial. Ann Intern. Med. 2006; 144: 865–876.
18. Genovese M., Becker J., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353 (11): 1114–1123.
19. Petty R., Southwood T., Baum J. et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J. Rheumatol. 1998; 25 (10): 1991–1994.
20. Wallace C., Ruperto N., Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
21. Ruperto N., Martini A. Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin. Exp. Rheumatol. 2001; 19.4 (Suppl. 23): 1–172.
22. Ruperto N., Ravelli A., Pistorio A. et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin. Exp. Rheumatol. 2001; 19. 4 (Suppl. 23): 1–9.
23. Singh G., Athreya B., Fries J. et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994; 37 (12): 1761–1969.
24. Giannini E., Ruperto N., Ravelli A. et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40 (7): 1202–1209.
25. Brunner H., Lovell D., Finck B. et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J. Rheumatol. 2002; 29 (5): 1058–1064.
26. Ruperto N., Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Current. opinion. in rheumatology. 2004; 16 (5): 566–570.
27. Moher D., Schulz K., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357 (9263): 1191–1194.
28. Ruperto N., Lovell D., Quartier P. et al., for PRINTO and PRCSG. Efficacy and safety of abatacept in children with juvenile idiopathic arthritis: A randomized, double-blind, placebocontrolled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.
29. Ruperto N., Lovell D., Quartier P. et al., for PRINTO and PRCSG. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010. in press.
Review
For citations:
Ruperto N. ABATACEPT: A NEW CHOICE FOR CHILDREN WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS. Current Pediatrics. 2010;9(2):32-39.
Email this article 
